🔊CEOInterviews

Ming Hsieh on biometrics

From ECE Pioneer - Ming Hsieh · · USC Electrical and Computer Engineering

“Los Angeles County Department of Social Services issued an RFP for fingerprint application and six months after deployment we landed a $16 million contract — within six months they recovered the full cost of the four‑year contract because the ID system deterred repeat fraudulent collections.”

Ming Hsieh
Chairman & Chief Executive Officer, FULGENT GENETICS INC
Policy Impact biometricspublic policywelfare fraudgovernment contracting

On , Ming Hsieh, Chairman & Chief Executive Officer at FULGENT GENETICS INC, spoke about biometrics during ECE Pioneer - Ming Hsieh on USC Electrical and Computer Engineering.

ECE Pioneer - Ming Hsieh
Watch on YouTube at 47:38
ECE Pioneer - Ming Hsieh
Watch on YouTube at 47:38
Talk by Ming Hsieh of his journey.
Ming Hsieh

About Ming Hsieh

Chairman & Chief Executive Officer · FULGENT GENETICS INC

Ming Hsieh, chairman and chief executive officer of Fulgent Genetics, spoke at a December 2024 event at the University of Southern California about his career and the company's growth. He said that when the COVID-19 pandemic began, Fulgent quickly shifted its capabilities to COVID-19 testing and became one of the top three companies in that market, generating more than $1.5 billion in cash from operations that he stated would be used to support cancer research. Hsieh also discussed his earlier work in biometrics, noting that a fingerprint identification system his company developed received a sole-source contract valued at about $500 million from the Department of Homeland Security. In a 2021 speech at the National Committee on U.S.-China Relations gala, Hsieh said he was a beneficiary of stable and collaborative U.S.-China relations, which he stated allowed him to change from a field farmer to a member of the National Academy of Engineering. He has also spoken about his philanthropic efforts, saying he has donated more than $100 million to support research, educational, and medical institutions. During a 2021 earnings call, Hsieh said the company expected revenue to nearly double in 2021 compared to the record revenue achieved in 2020.

Profile compiled from Ming Hsieh's verified public interviews and appearances. See all quotes & transcripts →

More from Ming Hsieh FULGENT GENETICS INC (FLGT) Full Transcript Explore All Executives